NCT03223428View on ClinicalTrials.gov

Real-world Evidence Study EvaLuating PAtient-Reported Outcomes With XERMELO

CompletedOBSERVATIONAL
Enrollment

223

Participants

Timeline

Start Date

June 22, 2017

Primary Completion Date

January 14, 2022

Study Completion Date

January 14, 2022

Conditions
Carcinoid Syndrome
Interventions
DRUG

Xermelo

This study will include patients with carcinoid syndrome who are initiating treatment with XERMELO.

Trial Locations (1)

27709

RTI-HS, Research Triangle Park

All Listed Sponsors
lead

TerSera Therapeutics LLC

INDUSTRY

NCT03223428 - Real-world Evidence Study EvaLuating PAtient-Reported Outcomes With XERMELO | Biotech Hunter | Biotech Hunter